Melinta Therapeutics Inc. (fka MLNTQ)

[ClayTrader]

* * $MLNT Video Chart 07-03-2019 * *

Link to Video - click here to watch the technical chart video

[Babubd]

As per CNN Business Stock Price Forecast, The 4 analysts offering 12-month price forecasts have a median target of $30.00, with a high estimate of $70.00. 52-wk high was $42.70. MLNT is heading to 50 Dollars plus. Mark my words!

[whytestocks]

News: $MLNT X-Biotix Therapeutics Joins Antimicrobials Working Group

WASHINGTON , July 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of X-Biotix Therapeutics, Inc. (X-Biotix) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new additi...

Find out more https://marketwirenews.com/news-releases/x-biotix-therapeutics-joins-antimicrobials-working-group-8440706.html

[Babubd]

52-wk high is $35. As per CNN Business Stock Price Forecast on Melinta (MLNT) The 4 analysts offering 12-month price forecast have a median target of 30.00, with a high estimate of 70.00. Where is MLNT heading to? Low float. 50 dollars plus+++.

[kevgan9]

It's moving quick

[logsplitter]

Exciting times

[View2Live4]

https://money.cnn.com/quote/forecast/forecast.html?symb=MLNT

[View2Live4]

Go to Yahoo finance and read the posts under this ticker... I got caught holding some too, but will see what happens. They had a meeting today for the company.

[mstgvic]

Anyone see the sell off coming. This is concerning.

Thanks, Red

[ClayTrader]

* * $MLNT Video Chart 06-20-2019 * *

Link to Video - click here to watch the technical chart video

[LG91]

$ 9.0 today $ 10 to $ 11 tomorrow

[BareTrap4239]

$MLNT is gonna run!!!! The drug provides another safe and effective pneumonia Treatment... Trust me I'm a pharmacist

[Babubd]

As per CNN Business Stock Price Forecast on Melinta (MLNT), The 4 analysts offering 12-month price forecasts have a median target of $30.00, with a high estimate of $70.00. 52-wk high was $42.70. U.S. FDA just accepted Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia. Float is only 8 million shares. MLNT can hit over $100. Cheers

[Benjaminjasper]

EDSA running on fda news!!

[crudeoil24]

6.58 in PM. Up,up, and away! MLNT

[BareTrap4239]

$MLNT Buy buy buy trust me I'm a pharmacist..

[Babubd]

52-wk high was $42.70. MLNT announces U.S. FDA Acceptance of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia. This is huge. Very low float. MLNT can hit $50 this week.

[ClayTrader]

* * $MLNT Video Chart 06-19-2019 * *

Link to Video - click here to watch the technical chart video

[boston127]

The OS has turned over 8 times today.

Gotta wonder if there is a ton of day trading. I got out in the mid 5s this AM. The volatility pause cost me. May jump back in tomorrow because the applications for this medicine are worldwide. Looking for a dip tomorrow AM before I get back in.

[davidsson10]

MLNT...

98% daily gain...

Booked and banked...

$MLNT

[whytestocks]

News: $MLNT MLNT Stock Moves Up Big On FDA Boost: Baxdela sNDA

MLNT stock more than tripled following Melinta Therapeutics Inc (NASDAQ:MLNT) announcing that its supplemental New Drug Application (sNDA) for Baxdela was approved by the FDA. Big Day for MLNT Stock Connecticut-based Melinta Therapeutics, which is involved in the development and marketi...

Got this from https://marketwirenews.com/news-releases/mlnt-stock-moves-up-big-on-fda-boost-baxdela-snda-8383710.html

[TradeSmart.ai]

Can we hit $12-$15 tomorrow would be very nice $MLNT

[JJGl]

Loaded this dip

[JJGl]

Looking to average up for tomorrow. $10+ possible

[TradeSmart.ai]

Should have kept my shares from April lol $MLNT

[TradeSmart.ai]

Call me crazy, but I added up here $MLNT

[alewis520]

$7 is up

[cjstocksup]

Out on my limit sell at $6.86. What an awesome day! Best $$$ gainer of the week for me so far looking forward to more this week in other hot news stocks. GL.

[crudeoil24]

MLNT is great $$$$$ opportunity.

[cjstocksup]

MLNT is running on air now we could soon be over $7.00 and $8.00 this afternoon. We broke $6.00 way easier than I thought and fast also.

[JJGl]

Will be looking for news of upgraded performance and target price.

[crudeoil24]

Shares of Melinta Therapeutics Inc. (MLNT) more than doubled (up 128%) on heavy volume Wednesday, after the antibiotics developer said its supplemental new drug application (sNDA) for Baxdela was accepted by the U.S. Food and Drug Administration. Trading volume spiked to over 4.7 million shares, compared with the full-day average of about 334,000 shares through Tuesday, and enough to make the stock the most actively traded ahead of the open. The company said the FDA has granted "priority review" status for Baxdela, in which the sNDA seeks to expand the current indication to include adult patients with community-acquired bacterial pneumonia (CABP). "BAXDELA's potency and activity against the most common bacterial pathogens seen in CABP indicate it could play a significant role in the treatment of this life-threatening illness, if approved," said Melinta Chief Medical Officer Sue Cammarata. "We look forward to working with the FDA to help evaluate bringing this potential option to people with CABP as soon as possible." The stock has tumbled 50% year to date through Tuesday, while the S&P 500 has gained 16%.

-Tomi Kilgore

For more from MarketWatch: http://www.marketwatch.com/newsviewer

(END) Dow Jones Newswires

June 19, 2019 09:25 ET (13:25 GMT)

[crudeoil24]

My initial order in on dip @ 4.24 > super low 7M share float.

[cjstocksup]

MLNT ran huge after the open. Re loading down here in the $4.30 range for the rest of the day run. I bet we see the $6.00 to $7.00 range later today with this float.

[whytestocks]

News: $MLNT Melinta Therapeutics Announces U.S. FDA Acceptance of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia

~ Application Seeks to Expand Label to Include an Indication and Phase III Data for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia (CABP) ~ ~ PDUFA Date Set for October 24, 2019 ~ MORRISTOWN, N.J., June 19, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, ...

Got this from https://marketwirenews.com/news-releases/melinta-therapeutics-announces-u-s-fda-acceptance-of-supplemental-new-drug-application-for-baxdela-xae-delafloxacin-for-the-treatment-of-community-acquired-bacterial-pneumonia-8380734.html

[boston127]

FDA approval. Very few OS shares.

Melinta Therapeutics Inc. (MLNT) shares were higher premarket after the company said the U.S. Food and Drug Administration accepted a supplemental New Drug Application for Baxdela for priority review.

Shares rose 45% to $2.87 premarket.

The sNDA filing seeks to expand the current indication for Baxdela to include adult patients with community-acquired bacterial pneumonia.

The FDA granted priority review status based on the previous Qualified Infectious Disease Product designation, which provides certain incentives for the development of antibacterial and antifungal treatments for serious or life-threatening infections. The FDA assigned a proposed review deadline of Oct. 24.

Baxdela was approved by the FDA in 2017 for the treatment of adult patients with acute bacterial skin and skin structure infections caused by designated susceptible bacteria.

[dj1216]

POSITIVE PHASE 3 RESULTS!!!!

[TeddyCaswell]

Boom

[Leonard McKinley]

Looking like garbage today. These fools think they have the marketing capability to make things happen. They do not. The revenue results stink. Furthermore, they have run up debt. They now have twice the debt that they have in market value equity. In other words, they are financially over-leveraged and at risk of bankruptcy. They company should be sold immediately to the highest bidder.

[TradeSmart.ai]

Looking good today $MLNT

[Sangster17]

A lot of buying after hours. Shot up to $5.15. It’s going to be explosive!

[TradeSmart.ai]

Looking good Premarket good morning everyone!!! $MLNT

[TradeSmart.ai]

739% Increase in revenue for the 4th quarter of 2018 at $35.5 million, year over year

Total revenue for the year is $96.4 million

52-wk high was $46.00 52-week low was $3.22

Insider and Institutional Ownership at 60%



https://marketwirenews.com/news-releases/melinta-therapeutics-announces-multiple-presentations-at-the-29th-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid--7962006.html

MORRISTOWN, N.J., April 08, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that researchers are scheduled to present multiple scientific data presentations with data from its antibiotic portfolio at this year’s 29th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), April 13-16 in Amsterdam, Netherlands.


“The body of data presented at ECCMID represents an important step in the global fight against antimicrobial resistance and delivering anti-infective solutions to patients,” said Sue Cammarata, M.D., chief medical officer of Melinta. “We are pleased that these data will be shared within the infectious disease community to further elucidate the value and utility of these anti-infective agents.”

Key data presentations at ECCMID 2019 include:

Integrated Symposium Presentations
•“Update on acute bacterial skin and skin structure infection: current challenges and new therapeutic agents,” chaired by Javier Garau, M.D., Ph.D. (Saturday, April 13, 1:30 - 3:30 p.m., Hall D)

•“Light and shadows in the management of serious MDR G-negative infections,” chaired by Matteo Bassetti, M.D. (Monday, April 15, 4:00 p.m. – 6:00 p.m., Hall F)

Oral Presentation
•Abstract No. 3623 (Sunday, April 14, 11:00 a.m. - 12:00 p.m. CET, Exhibit Hall L): Development and Validation of a Risk Stratification Score for a Mixed Gram-Negative and Gram-Positive Infections among Patients Hospitalized with Skin and Skin Structure Infections in the U.S., Y. Tabek, BD.

Poster Presentations

Meropenem/vaborbactam (VABOMERE®)
•Abstract No. 8308 (Saturday, April 13, 3:30 - 4:30 p.m. CET, Paper Poster Area): Activity of meropenem-vaborbactam and single-agent comparators against KPC-producing Enterobacterales isolates from European countries (2016-2018) stratified by infection type, M. Castanheira, JMI Laboratories

•Abstract No. 2825 (Monday, April 15, 12:30 - 1:30 p.m. CET, Paper Poster Area): Multicenter Evaluation of Meropenem/Vaborbactam MIC Results for Enterobacteriaceae and Pseudomonas aeruginosa Using MicroScan Dried Gram-Negative MIC Panels, A. Harrington, Loyola University

•Abstract No. 4780 (Monday, April 15, 12:30 - 1:30 p.m. CET, Paper Poster Area): ETEST meropenem/vaborbactam for antimicrobial susceptibility testing of Enterobacterales and Pseudomonas aeruginosa: performance results from a multi-centre study, C. Anglade, bioMérieux, Inc.

•Abstract No. 7426 (Tuesday, April 16, 12:30 - 1:30 p.m. CET, Paper Poster Area): An FDA-approved study for an AST disc 510(k) submission: comparison of an oxoid AST disc to a predicate AST disc for meropenem-vaborbactam, N. Hunter, Thermo Fisher Scientific

Delafloxacin (BAXDELA®)
•Abstract No. 6363 (Monday, April 15, 1:30 - 2:30 p.m. CET, Paper Poster Area): Delafloxacin tentative ECOFF values for common Gram-positive and Gram-negative bacteria, G. Menchinelli, Università Cattolica del Sacro Cuore

Oritavancin (ORBACTIV®)
•Abstract No. 4151 (Monday, April 15, 1:30 - 2:30 p.m. CET, Paper Poster Area): Oritavancin Activity against Staphylococcus aureus Clinical Isolates Causing Serious Infections in Hospitalized Patients in Europe (2017-2018), C. Carvalhaes, JMI Laboratories

[ClayTrader]

* * $MLNT Video Chart 04-08-2019 * *

Link to Video - click here to watch the technical chart video

[TradeSmart.ai]

15 Min chart shows a very bullish breakout here now $MLNT

[TradeSmart.ai]

Added more here $MLNT

[TradeSmart.ai]

$MLNT Bounce off $5.00 at 2:00 back to $5.50 by 2:45 then should bust loose from there.

[TradeSmart.ai]

$5.50 break inbound then next $6.00 $MLNT

[TradeSmart.ai]

Will be putting a DD packet together tonight $MLNT

[TradeSmart.ai]

Wow!!! Thank you will add to my DD $MLNT